Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Evolving Strategies in Pulmonary Embolism: From Risk Stratification to Interventional Therapy
Author(s): Stavros Konstantinides , José M Montero-Cabezas , Mario Iannaccone , et al Added: 2 months ago
This expert-led, on-demand programme explores the latest evidence and interventional strategies for intermediate-high and high-risk pulmonary embolism (PE). Chaired by Prof Stavros Konstantinides (University of Mainz, Mainz, DE) and featuring renowned specialists Dr José Montero-Cabezas (Leiden University Medical Center, Leiden, NL), Dr Mario Iannaccone (Turin Nord Emergency Hospital, Turin, IT)… View more

Intervention
Evolving Strategies in Pulmonary Embolism: From Risk Stratification to Interventional Therapy
Author(s): Stavros Konstantinides, Sylwia Sławek-Szmyt, José M Montero-Cabezas ,et al Start date: Dec 04, 2025
STORM-PE: Novel Data Driving Change in PE TreatmentJoin us for an exclusive webinar chaired by Prof Konstantinides (Mainz, DE), offering a focused exploration of advanced treatment strategies for intermediate-high and high-risk pulmonary embolism (PE). Together with leading experts Dr Montero-Cabezas (Leiden, NL), Dr Iannaccone (Turin, IT) and Dr Sławek-Szmyt (Poznan, PL), this session will… View more

Intervention
AHA 23: The ORFAN Study
Author(s): Charalambos Antoniades Added: 2 years ago
AHA 23 — In this brief interview, we are joined by Prof Charalambos Antoniades (Oxford University, UK) to discuss the ORFAN trial, sponsored by the University of Oxford.ORFAN is a prospective, multicenter, observational study that collected CT scans, biological material and outcomes data to develop and validate biomarkers of cardiometabolic risk. The registry included 250000 unselected… View more

Digital Health

Prevention & Chronic Conditions
Interventional Treatment of IHR-PE
Author(s): Federica Fumarola , Francesco Colombo , Claudio Corsaro , et al Added: 8 months ago

Heart Failure
AI-OCT Predicts Outcomes by Identifying High-Risk Plaques
Added: 2 months ago Source:  Radcliffe Cardiology
An artificial intelligence (AI) algorithm can identify high-risk coronary plaques on optical coherence tomography (OCT) images and predict adverse outcomes, according to findings from the PECTUS-AI study.¹ The research suggests that AI-assisted analysis of the entire imaged vessel provides superior prognostic value compared to manual analysis of a target lesion alone.Coronary thin-cap… View more

Digital Health

Imaging & Diagnostics
ACC 2025: EVOLUT Low Risk 5Y Outcomes
Author(s): Michael J Reardon Added: 10 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical… View more

Intervention
EASD 2025 Highlights: Updates on Icosapent Ethyl and Cardiometabolic Risk
Author(s): Rahul Aggarwal , Dirk Müller-Wieland Added: 4 months ago
Filmed onsite at EASD 2025, this on-demand series features key insights from Prof Dirk Müller-Wieland and Dr Rahul Aggarwal to interpret the latest data on eicosapentaenoic acid(EPA), including the latest sub-analysis of the REDUCE-IT trial, whichanalysed the effectiveness of icosapent ethyl (IPE) on CV risk by triglyceride-glucose (TyG) index - an indicator of insulin resistance and risk of type… View more

Heart Failure

Prevention & Chronic Conditions
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Author(s): Michael J Reardon Added: 2 years ago
TCT 23 - In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from the EVOLUT Low-Risk Trial (NCT03635424), sponsored by Medtronic. The EVOLUT Low-risk trial is a multicenter, prospective, single-arm study which aimed to assess the procedural safety and efficacy of the Medtronic TAVR system in 150 patients with bicuspid… View more

Intervention
TCT 23: 5Y Outcomes From the PARTNER 3 Low-Risk Trial
Author(s): Martin B Leon Added: 2 years ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic… View more

Intervention